益肾化湿颗粒辅助治疗慢性肾小球肾炎的效果研究  

Effect of yishen huashi granule as an adjuvant therapy for chronic glomerulonephritis

作　　者：梁素忍[1] 郭志玲[1] 胡昭[2] 常洁[1] 刘俊英[1] 郭佳音[1] 陈豫闽[1] 李飞[1] 董少卿[1] 贾国强[1] LIANG Su-ren;GUO Zhi-ling;HU Zhao;CHANG Jie;LIU Jun-ying;GUO Jia-yin;CHEN Yumin;LI Fei;DONG Shao-qing;JIA Guo-qiang(Department of Nephrology,First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,Henan,China)

机构地区：[1]河南科技大学第一附属医院肾内科,河南洛阳471000 [2]山东大学齐鲁医院

出　　处：《中国校医》2020年第5期321-322,358,共3页Chinese Journal of School Doctor

基　　金：山东省重点研发课题项目(2017GSF21116)。

摘　　要：目的探究慢性肾小球肾炎患者应用益肾化湿颗粒辅助治疗的临床疗效。方法选择2017年3月1日-2019年3月1日在河南科技大学第一附属医院接受治疗的慢性肾小球肾炎患者120例作为临床研究对象,随机投掷硬币法分组。对照组60例患者应用氯沙坦钾片治疗,观察组60例患者应用氯沙坦钾片与益肾化湿颗粒联合治疗,比较所有患者治疗后的临床疗效以及对血清中白细胞诱素-1(LKN-1)、肿瘤坏死因子α(TNF-α)和白细胞介素13(IL-13)水平的影响情况。结果经治疗后,观察组患者的治疗总有效率为96.67%,高于对照组患者的73.33%(P<0.05);观察组患者的尿红细胞为(4.09±1.01)个/HP、24 h尿蛋白定量为(0.79±0.35)g/L、血尿素氮(BUN)为(9.11±2.65)mmol/L以及血肌酐(Scr)为(119.44±48.99)umol/L,均低于对照组患者水平(P<0.05):尿红细胞(6.20±1.98)个/HP、24 h尿蛋白定量(1.25±0.39)g/L、血尿素氮(BUN)(10.60±3.18)mmol/L以及血肌酐(Scr)(137.01±55.43)umol/L;观察组患者血清中IL-13水平为(12.08±2.24)ng/L、TNF-α为(13.57±4.34)ng/L、LKN-1为(70.43±33.88)pmol/L,均低于对照组患者水平,差异均具有统计学意义(P<0.05)。结论应用益肾化湿颗粒治疗慢性肾小球肾炎患者,可有效消除炎症,改善肾功能,提高临床治疗效果,值得推广应用。Objective To explore the clinical efficacy of yishen huashi granule,a Chinese patent medicine in the treatment of chronic glomerulonephritis.Methods A total of 120 patients with chronic glomerulonephritis who were treated in the First Affiliated Hospital from March 1,2017 to March 1,2019 were randomly divided into a control group and a trial group,with 60 cases in each group.The patients in the control group were treated with losartan potassium,and the patients in the trial group were treated with the combination of yishen huashi granule and losartan potassium.The clinical efficacies and the levels of serum leukocyte-1(LKN-1),tumor necrosis factor alpha(TNF-alpha),and interleukin-13(IL-13)were investigated and compared between the two groups after the treatment.Results After the treatment,the total effective rate of the trial group was 96.67%,which was higher than that of the control group(73.33%).The urinary erythrocyte was(4.09±1.01)/HP,24-hour urinary protein was(0.79±0.35)g/L,blood urea nitrogen(BUN)was(9.11±2.65)mmol/L,and serum creatinine(Scr)was(119.44±48.99)umol/L in the trial group,which were significantly lower than those in the control group[urinary erythrocyte was(6.20±1.98)/HP,24-hour urine protein was(1.25±0.39)g/L,BUN was(10.60±3.18)mmol/L,and Scr was(137.01±55.43)umol/L].In the trial group,the average level of IL-13 was(12.08±2.24)ng/L,the average level of TNF-α was(13.57±4.34)ng/L,and the average level of LKN-1 was(70.43±33.88)pmol/L,all of which were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of Yishen huashi granule in the treatment of chronic glomerulonephritis can eliminate inflammation,improve renal function,and improve the clinical efficiency,so it is worthy of popularization in the clinic.

关 键 词：慢性肾小球肾炎 益肾化湿颗粒 白细胞诱素-1 肿瘤坏死因子Α 白细胞介素-13 

分 类 号：R453[医药卫生—治疗学]